Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours

Kathleen N Moore,¹ Todd M Bauer,² Gerald S Falchook,³ Swapan Chowdhury,⁴ Chirag Patel,⁴ Rachel Neuwirth,⁴ Aaron Enke,⁴ Fabian Zohren,⁴ Manish R Patel⁵

ABSTRACT

Background Sapanisertib (TAK-228) is an investigational, orally available, potent and highly selective mTORC1/2 inhibitor demonstrating promise in numerous malignancies. This phase I study (NCT02412722) evaluated the safety, tolerability, pharmacokinetics and antitumour activity of single-agent TAK-228 (milled capsules), administered daily (QD) or weekly (QW) and in combination with paclitaxel in patients with advanced solid tumours. Pharmacokinetic comparisons of milled versus unmilled TAK-228 and the impact of food were also investigated.

Methods Patients were enrolled to receive: TAK-228 QD, TAK-228 3 days/week plus paclitaxel 80 mg/m² days 1, 8, 15 (TAK-228+P) or TAK-228 QW (all 28-day cycles); starting TAK-228 doses were 4, 6 and 20 mg, respectively.

Results Sixty-one adults were enrolled. Maximum tolerated doses for milled TAK-228 were 3 mg (TAK-228 QD), 6 mg (TAK-228+P) and 30 mg (TAK-228 QW). Most patients reported ≥1 adverse event (AE); there were no meaningful differences in drug-related AEs across regimens or doses. Three on-study deaths occurred, all considered unrelated to study drugs. TAK-228 pharmacokinetics did not differ between unmilled/milled capsules or with/without paclitaxel. However, TAK-228 Cₘ₉₉ decreased by ~40% in fed versus fasted patients. Objective response rates were 12% (TAK-228 QD), 18% (TAK-228+P) and 0% (TAK-228 QW). One patient receiving TAK-228+P had a complete response; three patients receiving TAK-228+P and two patients receiving TAK-228 QD had partial responses.

Conclusions Milled TAK-228 was well tolerated with signs of antitumour activity; administration did not reduce overall exposure (area under the plasma concentration–time curve) but reduced Cₘ₉₉, which is expected when dosed in the fed state. These promising findings warrant further investigation.

Trial registration number NCT02412722.

INTRODUCTION

The mammalian (or ‘mechanistic’) target of rapamycin (mTOR) is a serine/threonine kinase activated by external stimuli via the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinases signalling pathways.¹ mTOR forms two distinct multisubunit complexes, mTORC1 and mTORC2, to regulate protein expression,
cell growth, survival, actin cytoskeletal dynamics and metabolism. Aberrant mTOR signalling is common in cancer and contributes to solid tumour development and progression.2,3

First-generation mTOR inhibitors, such as sirolimus (rapamycin), everolimus and temsirolimus, are allosteric inhibitors that primarily inhibit mTORC1.4 However, rapamycin and its analogues may inadvertently upregulate protein kinase B (Akt) activity and paradoxical hyperactive signalling, which can lead to enhanced survival of tumour cells and chemoresistance.4,5 Furthermore, evidence suggests that a temsirolimus-resistant phenotype may be mediated through the activation of signal transduction pathways via mTORC2, not mTORC1; hence, new agents capable of dual mTORC1/2 inhibition may be preferable to existing drugs that target only mTORC1.

TAK-228 is an investigational, orally available and highly selective ATP-competitive inhibitor of both mTORC1 and mTORC2.6 TAK-228 is being developed both as monotherapy and in combination with other agents for the treatment of advanced solid tumours and has demonstrated an acceptable safety profile and preliminary therapeutic activity in two phase I trials.7,8 Both studies used capsules of TAK-228 comprising unmilled active pharmaceutical ingredient, which patients took with a light meal. Subsequent improvements to the TAK-228 manufacturing process included a physical milling step following granulation to improve particle size distribution and enable automated capsule filling for scaling-up manufacturing.9,10 Initial pharmacokinetic (PK) simulations using GastroPlus (Simulations Plus, Lancaster, California, USA) suggested that milled and unmilled TAK-228 capsules dosed up to 6 mg under fasting conditions would result in similar maximum plasma concentrations (Cmax) and exposure as measured by the area under the concentration–time curve (AUC). However, under fed conditions, milled TAK-228 was predicted to have 65% higher Cmax and earlier time of maximum plasma concentration (Tmax) compared with unmilled TAK-228, with no meaningful differences in the AUC (data on file). In order to enable the integration of the new milled capsule formation of TAK-228 into the clinical development programme and to understand the safety data in the context of the historic PK and safety data for TAK-228, an evaluation of the PK of TAK-228 comparing the different dosing conditions and formulations was important.

This phase I study (NCT02412722; MLN0128-1004) evaluated the safety, tolerability, PK and preliminary efficacy of milled TAK-228 capsule formulation administered as a single agent and in combination with paclitaxel under fasted dosing conditions in adult patients with advanced non-haematological malignancies. The study also evaluated the effect of food (fasted or with a high-fat meal) and manufacturing process (ie, milled vs unmilled TAK-228) on the PK of TAK-228 capsules.

METHODS
Study design
This open-label, phase I study was conducted in adult patients with advanced non-haematological malignancies across four sites in the USA. The primary objectives were to evaluate the safety and tolerability of milled TAK-228 as a single agent and in combination with paclitaxel, to characterise the effect of dosing condition (fasted or with a high-fat meal) on the PK of TAK-228 and to characterise the PK of milled TAK-228 taken under fasted conditions ~24 hours after paclitaxel infusion. The secondary objectives were to characterise the PK of milled versus unmilled TAK-228 (fasted conditions) and to evaluate the preliminary efficacy of milled TAK-228 (as a single agent and in combination with paclitaxel).

Patients were assigned to one of three treatment arms (online supplementary figure 1) at the discretion of the investigator and based on cohort availability: (1) milled TAK-228 once daily (QD) on days 1–28 (starting dose 4 mg); (2) milled TAK-228 QD for 3 days per week on days 2–4, 9–11, 16–18 and 23–25 (starting dose 6 mg) and paclitaxel (P) intravenous infusion on days 1, 8, and 15 dosed ~24 hours prior to TAK-228; and (3) milled TAK-228 administered once weekly (QW) on days 1, 8, 15 and 22 (starting dose 20 mg). Patients enrolled in the TAK-228 QD arm also participated in a PK run-in period conducted ≤14 days prior to cycle 1 day 1 (online supplementary figure 1). On three separate visits separated by ≥48 hours during the PK run-in period, patients received unmilled TAK-228 4 mg on an empty stomach (visit 1), milled TAK-228 4 mg after a high-fat breakfast (visit 3) and milled TAK-228 4 mg on an empty stomach (visit 5). Collection of PK samples at 24 hours post-dose timepoints were conducted during visits 2, 4 and 6. Patients in all treatment arms received TAK-228 in repeated 28-day cycles until disease progression or unacceptable toxicity.

Starting doses of TAK-228 were based on previously observed maximum tolerated doses (MTDs)7,11 and the expectation that milled TAK-228 formulations would increase drug exposure. Enrolment into further dosing cohorts was dependent on the observation of dose-limiting toxicities (DLTs) according to dose escalation rules outlined in online supplementary figure 2. DLTs were defined as adverse events (AEs) associated with the study drug serious enough to prevent further increases in the dosage. Details of specific DLTs are included in the appendix. The MTD was defined as the dose of TAK-228 resulting in ≤1 DLT in cycle 1 in all treatment arms.

A minimum of 16 patients completing the protocol in the single-agent TAK-228 QD treatment arm was selected as adequate to enable precision in estimating geometric mean ratios. Sample sizes for TAK-228 QW and TAK 228+P arms were based on clinical considerations.

Patients
The study enrolled patients aged ≥18 years with advanced non-haematological malignancy who had failed on, or
were not eligible for, standard-of-care therapy. Key inclusion criteria included adequate organ function, Eastern Cooperative Oncology Group performance status of 0–1 and no more than four prior lines of cytotoxic chemotherapy. Patients were excluded if they had received diagnosis of a primary, untreated metastatic brain tumour, history of leptomeningeal disease or spinal cord compression. Further exclusion criteria included failure to recover from reversible side effects of anticancer therapy, poorly managed diabetes mellitus, significant cardiovascular or pulmonary disease within the 6 months prior to study start and manifestations of gastrointestinal malabsorption. Patients participating in the TAK-228 QD PK run-in were excluded if they had used proton pump inhibitors within 5 days or H₂-receptor antagonists within 24 hours of the first PK run-in dose.

Informed written consent was obtained from all patients.

Assessments
Serial blood samples for PK analysis were taken 30 min prior to administration of TAK-228 and 30 min, 1, 2, 3, 4, 6, 8 and 24 hours after administration of TAK-228 on visits 1, 3 and 5 of the QD run-in period, day 2 of cycle 1 in the TAK-228+P arm (first day of TAK-228 treatment) and day 1 of cycle 1 of the TAK-228 QW arm. Blood samples were analysed using liquid chromatography with tandem mass spectrometry (Frontage Laboratories, Inc.), validated over the concentration range 1–1000 ng/mL.

AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 and coded to standardised terms using the Medical Dictionary for Regulatory Activities version 19.0. Serious AEs (SAEs) and AEs were recorded from the first dose of the study drug through 30 days after the last dose administration. The potential relatedness of an AE to the study drug was determined by the investigator.

Disease status and best overall response, objective response rate (ORR; complete response (CR)+partial response (PR)) and clinical benefit rates (CR+PR+stable disease (SD) and CR+PR+SD for ≥6 months) were assessed in accordance with the Response Evaluation Criteria in Solid Tumours (version 1.1) guidelines using contrast CT or MRI of the chest, abdomen and pelvis. Bone scans could be used in place of CT or MRI in patients with bone metastases. Baseline scans were taken within 4 weeks of the first administration of study drug, and subsequent assessments were carried out on day 1 of cycle 3 and every two cycles thereafter until the end of the study or treatment discontinuation. The same imaging modality was used for each patient throughout the study.

Statistical methods
The PK population, which was used for all PK analyses, included all patients with protocol-specified dosing, conditions and PK data required to reliably estimate PK parameters. The DLT- evaluable population comprised all patients who received ≥75% of planned TAK-228 doses in cycle 1 or who stopped taking TAK-228 before receiving 75% of the planned TAK-228 doses because of a drug-related AE.

RESULTS
From 26 March 2015 to 30 June 2016, 61 patients (age range, 28–88 years) with non-haematological malignancies (most commonly stage IV) were enrolled and received at least one dose of study drug (TAK-228 QD, n=19; TAK-228+P, n=22; TAK-228 QW, n=20) (table 1). The most commonly diagnosed cancers were uterine cancer (n=7), colon cancer (n=6) and ovarian cancer (n=5). At data cut-off, 56 patients had discontinued (26 due to progressive disease, 8 due to AEs, 7 withdrew, 1 was lost to follow-up and 14 for other reasons), with five ongoing.

DLTs and MTD determination
In the TAK-228 QD arm, 3/6 DLT-evaluable patients receiving TAK-228 4 mg experienced at least one DLT (grade 3 fatigue; grade 3 fatigue, macular rash and decreased appetite; and grade 2 and 3 rash). Of the 10 patients enrolled to receive TAK-228 3 mg, one patient experienced a DLT (grade 3 thrombocytopenia). Thus, the MTD and recommended phase II dose (RP2D) for single-agent QD milled TAK-228 was established as 3 mg. In the TAK-228+P arm, one of seven patients receiving TAK-228 6 mg experienced three DLTs (grades 2 and 3 fatigue and grade 3 dehydration), and nine SAEs in four patients were considered related to treatment; on expansion of the 6 mg cohort to 12 patients, no additional DLTs were observed within cycle 1, but five of these 12 patients required a reduction in TAK-228 in subsequent cycles. No DLTs were observed in a separate cohort (n=7, 6 DLT evaluable) given TAK-228 4 mg plus paclitaxel. Thus, when given in combination with paclitaxel 80 mg/m², TAK-228 4 mg was identified as the RP2D, and TAK-228 6 mg was determined as the MTD. In the TAK-228 QW arm, none of the six patients receiving 20 mg experienced a DLT. A subsequent cohort initially consisting of six DLT- evaluable patients was given TAK-228 30 mg QW, with none experiencing DLTs; on cohort expansion to 12 patients, 1
Table 1  Patient demographics and baseline characteristics

|                     | TAK-228 QD | TAK-228+P | TAK-228 QW |
|---------------------|------------|-----------|------------|
|                     | 3 mg (n=11)| 4 mg (n=8) | Total (n=19)| 4 mg (n=7) | 6 mg (n=15) | Total (n=22) | 20 mg (n=7) | 30 mg (n=13) | Total (n=20) |
| Median age, years (range) | 65 (35–88) | 61 (46–73) | 62 (35–88) | 52 (49–68) | 65 (34–81) | 63 (34–81) | 61 (28–76) | 66 (39–79) | 64 (28–79) |
| Female, n (%)        | 9 (82)     | 6 (75)    | 15 (79)    | 5 (71)     | 11 (73)    | 16 (73)    | 3 (43)     | 10 (77)    | 13 (65)    |
| Race, n (%)          |            |           |            |            |            |            |            |            |            |
| White                | 9 (82)     | 7 (88)    | 16 (84)    | 6 (86)     | 11 (73)    | 17 (77)    | 5 (71)     | 11 (85)    | 16 (80)    |
| Black or African-American | 1 (9)   | 1 (13)    | 2 (11)     | 1 (14)     | 2 (13)     | 3 (14)     | 1 (14)     | 1 (8)      | 2 (10)     |
| Other                | 1 (9)      | 0         | 1 (5)      | 0          | 2 (13)     | 2 (9)      | 1 (14)     | 1 (8)      | 2 (10)     |
| ECOG PS              |            |           |            |            |            |            |            |            |            |
| 0                    | 5 (46)     | 3 (38)    | 8 (42)     | 2 (29)     | 7 (47)     | 9 (41)     | 3 (43)     | 4 (31)     | 7 (35)     |
| 1                    | 6 (55)     | 5 (63)    | 11 (58)    | 5 (71)     | 8 (53)     | 13 (59)    | 4 (57)     | 9 (69)     | 13 (65)    |
| Primary diagnosis, n (%) |            |           |            |            |            |            |            |            |            |
| Anal                 | –          | –         | –          | 1 (14)     | 0          | 1 (5)      | –          | –          | –          |
| Bile duct            | –          | –         | –          | 1 (14)     | 1 (7)      | 2 (9)      | 1 (14)     | 0          | 1 (5)      |
| Bone                 | –          | –         | –          | –          | –          | –          | 0          | 1 (8)      | 1 (5)      |
| Breast               | 0          | 1 (13)    | 1 (5)      | 1 (14)     | 1 (7)      | 2 (9)      | 0          | 1 (8)      | 1 (5)      |
| Colon                | 1 (9)      | 3 (38)    | 4 (21)     | –          | –          | –          | 1 (14)     | 1 (8)      | 2 (10)     |
| Endometrium          | 1 (9)      | 0         | 1 (5)      | –          | –          | –          | 0          | 1 (8)      | 1 (5)      |
| Fallopian tube       | 2 (18)     | 0         | 2 (11)     | –          | –          | –          | –          | –          | –          |
| Gall bladder         | –          | –         | –          | –          | –          | –          | 1 (14)     | 0          | 1 (5)      |
| Head/neck            | –          | –         | –          | 1 (14)     | 0          | 1 (5)      | 1 (14)     | 2 (15)     | 3 (15)     |
| Kidney               | 1 (9)      | 0         | 1 (5)      | –          | –          | –          | –          | –          | –          |
| Lung                 | –          | –         | –          | 0          | 2 (13)     | 2 (9)      | 1 (14)     | 1 (8)      | 2 (10)     |
| Neuroendocrine       | 0          | 1 (13)    | 1 (5)      | 0          | 1 (7)      | 1 (5)      | –          | –          | –          |
| Ovary                | 1 (9)      | 0         | 1 (5)      | 0          | 1 (7)      | 1 (5)      | 0          | 3 (23)     | 3 (15)     |
| Pancreas             | 1 (9)      | 0         | 1 (5)      | 0          | 1 (7)      | 1 (5)      | 0          | 1 (8)      | 1 (5)      |
| Peritoneum           | –          | –         | –          | 0          | 1 (7)      | 1 (5)      | –          | –          | –          |
| Prostate             | –          | –         | –          | 0          | 1 (7)      | 1 (5)      | –          | –          | –          |
| Rectal               | 1 (9)      | 0         | 1 (5)      | –          | –          | –          | 1 (14)     | 0          | 1 (5)      |
| Soft-tissue sarcoma  | 1 (8)      | 1 (13)    | 2 (11)     | 2 (29)     | 0          | 2 (9)      | –          | –          | –          |
| Stomach              | 0          | 1 (13)    | 1 (5)      | –          | –          | –          | –          | –          | –          |
| Thymus               | –          | –         | –          | –          | –          | –          | 1 (14)     | 0          | 1 (5)      |
| Unknown              | 1 (9)      | 0         | 1 (5)      | 0          | 1 (7)      | 1 (5)      | –          | –          | –          |

Continued
patient had a DLT (grade 3 adverse drug reaction). Both the MTD and RP2D for the TAK-228 QW were determined as 30 mg.

Safety and tolerability
Of 19 patients participating in the TAK-228 QD PK run-in, 17 participated in the QD treatment phase and were included in the safety analyses (n=59). With TAK-228 QD, patients received a median of three cycles (range, 1–13) and a mean (standard deviation) of 4.7 (4.1) cycles, with longer exposure for 3 versus 4mg (4 vs 1.5 cycles; 15.0 vs 7.4 weeks). With TAK-228+P, patients received a median of two cycles (range, 1–9) and a mean (standard deviation) of 3.2 (2.2) TAK-228 cycles; median duration of exposure was similar with TAK-228 4 and 6mg (7.6 and 7.7 weeks, respectively), as was median cumulative paclitaxel dose (478.9 and 479.1mg, respectively). With TAK-228 QW, patients received a median of two cycles (range 1–10) and a mean (standard deviation) of 2.7 (2.1) cycles; median duration of exposure was 7.1 weeks with both 20 mg and 30 mg TAK-228.

AEs were experienced by 100%, 96% and 95% of patients in the TAK-228 QD, TAK-228+P and TAK-228 QW arms, respectively; 94%, 96% and 80% were considered drug-related (table 2). The most common drug-related AEs of any grade were fatigue (59%), pruritus (41%), decreased appetite, diarrhoea and nausea (29% each) with TAK-229 QD; diarrhoea (64%), decreased appetite, fatigue, nausea (41% each) and stomatitis (36%) with TAK-228+P; and fatigue, nausea, vomiting (45% each) and diarrhoea (30%) with TAK-228 QW. The most common grade ≥ 3 AEs were macular rash, fatigue, hypona-teraemia and hyperglycaemia (12% each) with TAK-228 QD; neutropenia, fatigue (18% each), abdominal pain and hypophosphataemia (14% each) with TAK-228+P; and hyperglycaemia (15%), abdominal pain, anaemia, hypercalcicaemia, hypotension, nausea and vomiting (10% each) and TAK-228 QW (table 2).

AEs of interest for this study (hyperglycaemia, rash, renal insufficiency, mucosal inflammation and asthaenic conditions) were observed in ≥10% of patients in all treatment arms. Asteopathic conditions were the most common AE of interest, occurring in 59%, 55% and 60% of patients treated with TAK-228 QD, TAK-228+P and TAK-228 QW, respectively; these were mostly cases of fatigue.

SAEs were reported in 29% of patients treated with TAK-228 QD, 41% of patients treated with TAK-228+P and 50% of patients treated with TAK-228 QW (table 2). One patient receiving TAK-228 4mg QD, three patients receiving TAK-228+P 6mg and three patients receiving TAK-228 30 mg QW discontinued TAK-228 treatment due to AEs, and four patients discontinued paclitaxel. Three deaths occurred during the study, one in each treatment arm; none were considered related to study drugs.

PK profile
There were no appreciable differences in the concentration–time profile or PK parameters of TAK-228

---

Table 1

| Disease stage at initial diagnosis, n (%), | TAK-228 QD | TAK-228+P | TAK-228 QW |
|-----------------------------------------|------------|-----------|------------|
| I                                       | 1 (9)      | 2 (11)    | 2 (10)     |
| II                                      | 1 (9)      | 1 (14)    | 1 (10)     |
| III                                     | 3 (21)     | 3 (18)    | 4 (23)     |
| IV                                      | 5 (46)     | 3 (16)    | 3 (19)     |
| Missing                                 | 1 (9)      | 2 (25)    | 3 (16)     |

---

Moore KN, et al. ESMO Open 2018;3:e000291. doi:10.1136/esmoopen-2017-000291
Table 2  Safety profile of TAK-228 during the dosing phase, including all cause grade ≥3 AEs occurring in more than one patient and the most common any-grade drug-related AEs occurring in ≥15% of patients

| TAK-228 QD | TAK-228+P | TAK-228 QW |
|------------|------------|------------|
| 3mg (n=11) | 4mg (n=6)  | 6mg (n=15) |
| 20mg (n=7) | 30mg (n=13) | Total (n=20) |

| On-study deaths, n (%) | 0 | 1 (17) | 1 (6) | 0 | 1 (7) | 1 (5) | 0 | 1 (8) | 1 (5) |
| AE resulting in TAK-228 discontinuation, n (%) | 0 | 1 (17) | 1 (6) | 0 | 3 (20) | 3 (14) | 0 | 3 (23) | 3 (15) |
| AE resulting in paclitaxel discontinuation, n (%) | – | – | – | 0 | 4 (27) | 4 (18) | – | – | – |
| Drug-related SAE, n (%) | 0 | 0 | 0 | 1 (14) | 4 (27) | 5 (23) | 0 | 2 (15) | 2 (10) |
| SAE, n (%) | 3 (27) | 2 (33) | 5 (29) | 2 (29) | 7 (47) | 9 (41) | 4 (57) | 6 (46) | 10 (50) |
| Drug-related grade ≥3 AE, n (%) | 5 (46) | 5 (83) | 10 (59) | 2 (29) | 11 (73) | 13 (59) | 2 (29) | 4 (31) | 6 (30) |
| Grade ≥3 AE, n (%) | 6 (55) | 6 (100) | 12 (71) | 4 (57) | 11 (73) | 15 (68) | 5 (71) | 7 (54) | 12 (60) |
| Abdominal pain | 1 (9) | 0 | 1 (6) | 2 (29) | 1 (7) | 3 (14) | 1 (14) | 1 (8) | 2 (10) |
| Anaemia | 0 | 0 | 0 | 2 (13) | 2 (9) | 1 (14) | 1 (8) | 2 (10) |
| Asaesthesia | – | – | – | 1 (14) | 1 (7) | 2 (9) | – | – | – |
| Blood phosphorus decreased | 1 (9) | 0 | 1 (6) | 0 | 2 (13) | 2 (9) | – | – | – |
| Dehydration | – | – | – | 0 | 2 (13) | 2 (9) | – | – | – |
| Diarrhoea | 1 (9) | 0 | 1 (6) | 0 | 2 (13) | 2 (9) | 1 (14) | – | 1 (5) |
| Fatigue | 0 | 2 (33) | 2 (12) | 0 | 4 (27) | 4 (18) | – | – | – |
| Hypercalcaemia | – | – | – | – | – | – | 0 | 2 (15) | 2 (10) |
| Hyperglycaemia | 1 (9) | 1 (17) | 2 (12) | 0 | 1 (7) | 1 (5) | 0 | 3 (23) | 3 (15) |
| Hyponatraemia | 1 (9) | 1 (17) | 2 (12) | – | – | – | – | – | – |
| Hypophosphataemia | – | – | – | 0 | 3 (20) | 3 (14) | 0 | 1 (8) | 1 (5) |
| Hypotension | – | – | – | – | – | – | 2 (29) | 0 | 2 (10) |
| Nausea | – | – | – | 0 | 2 (13) | 2 (9) | 1 (14) | 1 (8) | 2 (10) |
| Neutropaenia | – | – | – | 0 | 4 (27) | 4 (18) | – | – | – |
| Rash macular | 1 (9) | 1 (17) | 2 (12) | – | – | – | – | – | – |
| Vomiting | – | – | – | 0 | 1 (7) | 1 (5) | 1 (14) | 1 (8) | 2 (10) |
| Drug-related AE, n (%) | 10 (91) | 6 (100) | 16 (94) | 7 (100) | 14 (93) | 21 (96) | 5 (71) | 11 (85) | 16 (80) |
| Abdominal pain | 2 (18) | 1 (17) | 3 (18) | – | – | – | – | – | – |
| Alopeica | – | – | – | 2 (29) | 2 (13) | 4 (18) | – | – | – |
| Asaesthesia | – | – | – | 1 (14) | 4 (27) | 5 (23) | 1 (14) | 0 | 1 (5) |
| Decreased appetite | 3 (27) | 2 (33) | 5 (29) | 3 (43) | 6 (40) | 9 (41) | 1 (14) | 2 (15) | 3 (15) |
| Dehydration | – | – | – | 0 | 4 (27) | 4 (18) | 1 (14) | 0 | 1 (5) |
| Diarrhoea | 2 (18) | 3 (50) | 5 (29) | 5 (71) | 9 (60) | 14 (64) | 4 (57) | 2 (15) | 6 (30) |
| Dry mouth | – | – | – | 2 (29) | 2 (13) | 4 (18) | 0 | 1 (8) | 1 (5) |
| Fatigue | 6 (55) | 4 (67) | 10 (59) | 1 (14) | 8 (53) | 9 (41) | 3 (43) | 6 (46) | 9 (45) |
| Hyperglycaemia | 2 (18) | 1 (17) | 3 (18) | 1 (14) | 3 (20) | 4 (18) | 0 | 3 (23) | 3 (15) |
| Nausea | 4 (36) | 1 (17) | 5 (29) | 4 (57) | 5 (33) | 9 (41) | 4 (57) | 5 (39) | 9 (45) |
| Neuropathy peripheral | – | – | – | 3 (43) | 2 (13) | 5 (23) | – | – | – |
| Neutropaenia | – | – | – | 0 | 4 (27) | 4 (18) | – | – | – |
| Pruritus | 4 (36) | 3 (50) | 7 (41) | – | – | – | 0 | 1 (8) | 1 (5) |
| Rash | 1 (9) | 2 (33) | 3 (18) | 1 (14) | 0 | 1 (5) | – | – | – |
| Rash (maculopapular) | 4 (36) | 0 | 4 (24) | 0 | 2 (9) | 0 | 2 (15) | 2 (10) |
| Stomatitis | 1 (9) | 2 (33) | 3 (18) | 4 (57) | 0 | 2 (9) | 0 | 2 (15) | 2 (10) |
| Vomiting | 1 (9) | 1 (17) | 2 (12) | 2 (29) | 5 (33) | 7 (32) | 2 (29) | 7 (54) | 9 (45) |

–, not applicable; AE, adverse event; QD, once daily; QW, once weekly; SAE, serious adverse event; TAK-228+P, TAK-228 QD 3 days/week+paclitaxel 80mg/m² on days 1, 8, 15.
Figure 1  Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period, according to manufacturing process and dosing conditions. *Geometric mean; †Median; ‡Arithmetic mean. ¬, not available/not applicable; AUC, area under the plasma concentration–time curve; CL/F, apparent oral clearance; Cmin, minimum plasma concentration; CV, coefficient of variation; t½, plasma half-life; TAK-228+P, TAK-228 once daily 3 days/week+paclitaxel 80 mg/m² on days 1, 8 and 15; Tmax, time of maximum plasma concentration; QW, once weekly; Vz/F, apparent terminal phase volume of distribution.

| PK parameters | Milled | Unmilled | Ratio* (90% CI) | Fed | Fasted | Ratio* (90% CI) |
|---------------|--------|----------|----------------|-----|--------|----------------|
| Cmin* ng/mL   | 36.4 (50.6) | 34.0 (48.1) | 1.07 (0.78, 1.47) | 21.6 (37.4) | 36.4 (50.6) | 0.59 (0.46, 0.76) |
| (n=17)        | n=19    |          |                | n=19 | n=17   |                 |
| AUCₐ₀→∞* hr-ng/mL (CV) | 316.5 (40.5) | 273.8 (40.5) | 1.16 (0.84, 1.60) | 262.5 (47.1) | 316.5 (40.5) | 0.83 (0.62, 1.10) |
| (n=13)        | n=14    |          |                | n=16 | n=13   |                 |
| AUCₐ₀→∞* hr-ng/mL (CV) | 229.2 (58.2) | 204.6 (57.3) | 1.12 (0.75, 1.68) | 205.9 (59.8) | 229.2 (58.2) | 0.90 (0.59, 1.36) |
| (n=17)        | n=19    |          |                | n=19 | n=17   |                 |
| AUCₘₚ* hr-ng/mL (CV) | 369.2 (50.0) | 400.8 (48.2) | 0.92 (0.67, 1.26) | 382.8 (64.7) | 369.2 (50.0) | 1.04 (0.72, 1.49) |
| (n=13)        | n=13    |          |                | n=13 | n=13   |                 |
| Tₘₚ* hr (range) | 2.0 (0.5–3.1) | 1.7 (0.5–6.1) | – | 6.0 (1.0–8.0) | 2.0 (0.5–3.1) | – |
| (n=17)        | n=19    |          |                | n=19 | n=17   |                 |
| t½* hr (SD)   | 8.3 (2.5) | 12.8 (8.0) | – | 10.6 (7.2) | 8.3 (2.5) | – |
| (n=13)        | n=13    |          |                | n=13 | n=13   |                 |
| CL/F* L/hr (CV) | 10.8 (47.0) | 10.0 (41.3) | 1.09 (0.79, 1.49) | 10.5 (62.1) | 10.8 (47.0) | 0.96 (0.67, 1.39) |
| (n=13)        | n=13    |          |                | n=13 | n=13   |                 |
| Vz/F* L (%)CV | 124.2 (29.4) | 153.4 (65.2) | 0.81 (0.61, 1.07) | 132.8 (29.6) | 124.2 (29.4) | 1.07 (0.88, 1.30) |
| (n=13)        | n=13    |          |                | n=13 | n=13   |                 |
administered as unmilled versus milled TAK-228 4 mg capsules in a fasted state (figure 1). Geometric mean $C_{\text{max}}$ (34.0 vs 36.4 ng/mL) for unmilled vs milled TAK-228 capsules, respectively) and median $T_{\text{max}}$ (1.7 vs 2.0 hours, respectively) were comparable between the two manufacturing processes. In contrast, there was a clinically significant reduction of ~40% in the geometric mean $C_{\text{max}}$ of milled TAK-228 capsules administered following consumption of a high-fat breakfast compared with administration on an empty stomach (21.6 vs 36.4 ng/mL, respectively) (figure 1), but no appreciable change in the geometric mean $C_{\text{max}}$ of TAK-228 following a high-fat meal versus in a fasted state (382.8 vs 369.2 hour-ng/mL, respectively). The mean $T_{\text{max}}$ of milled TAK-228 increased from 2.0 hours in the fasted state to 6.0 hours in the fed state (figure 1).

The PK of TAK-228 was consistent when administered as milled TAK-228 capsules on a QW schedule, with a dose-dependent increase in plasma exposure between the 20 mg and 30 mg doses (table 3). The plasma exposure of TAK-228 administered in combination with paclitaxel also increased in a dose-dependent manner between the 4 mg and 6 mg doses. PK parameters for TAK-228 in the combination arm (table 3) were consistent with PK for TAK-228 (4 mg, milled, fasted state) administered in the QD arm (figure 1), suggesting that administering paclitaxel 24 hours before TAK-228 had no clinically meaningful effects on TAK-228 PK.

**Tumour response**

With TAK-228 QD, two patients (one each with renal and uterine cancers (TAK-228 3 mg and 4 mg, respectively)) achieved a PR, equating an ORR of 12% (table 4). Seven patients had SD, four of whom maintained SD for ≥6 months: individual patients had SD duration of 208 days (TAK-228 3 mg; fallopian tube cancer), 220 days (TAK-228 3 mg; fallopian tube cancer), 253 days (TAK-228 3 mg; ovarian cancer) and 368 days (TAK-228 4 mg; colon cancer) (online supplementary figure 3). The overall clinical benefit rate (CR+PR + SD) was 52.9% (9/17 patients). Apart from a greater incidence of SD in patients receiving 3 mg TAK-228, there were no notable trends in efficacy across the different dose levels.

With TAK-228+P, one patient (breast cancer) achieved a CR and three achieved PRs (one each with urinary bladder and uterine cancers (both TAK-228 6 mg), one with soft-tissue sarcoma (TAK-228 4 mg), resulting in an ORR of 18% (table 4). Seven patients achieved SD; one patient with ovarian cancer receiving TAK-228 6 mg plus paclitaxel maintained SD for ≥6 months (220 days) (online supplementary figure 3). The overall clinical benefit rate with TAK-228+P was 50% (11/22 patients): no notable trends were observed between the 4 mg and 6 mg TAK-228 doses.

No patient achieved an objective response with TAK-228 QW. Nine patients achieved SD; one patient with head and neck cancer receiving TAK-228 30 mg QW maintained SD for ≥6 months (225 days) (online supplementary figure 3). The overall clinical benefit rate with TAK-228 QW was 45% (9/20 patients). No notable trends were observed between the 20 mg and 30 mg TAK-228 doses.

**DISCUSSION**

This phase I study was designed to evaluate the safety and tolerability and PK of the investigational oral mTORC1/2 dual inhibitor TAK-228 when administered as milled TAK-228 either as a single agent or in combination with paclitaxel and to assess the effect of dosing conditions (fasted vs fed) on the PK of TAK-228. In addition, the study compared the PK of milled versus unmilled TAK-228 capsules and evaluated the preliminary efficacy.

Table 3 Pharmacokinetic profile of TAK-228 given three times weekly in combination with paclitaxel (TAK-228+P) or as monotherapy once weekly (TAK-228 QW)

| Parameter | TAK-228+P | TAK-228 QW |
|-----------|-----------|-----------|
|           | 4 mg (n=7) | 6 mg (n=15) | 20 mg (n=7) | 30 mg (n=13) |
| $C_{\text{max}}$, ng/mL (CV) | 28.5 (64) | 65.7 (41) | 208.6 (17) | 235.2 (43) |
| $\text{AUC}_{\text{0-24hr}}$, hour-ng/mL | 124.1 (58) | 243.9 (34) | – | – |
| $\text{AUC}_{\text{0-24hr}}$, hour-ng/mL (CV) | – | – | 1238.1 (53) | 1528.8 (44) |
| $\text{AUC}_{\text{0-8hr}}$, hour-ng/mL (CV) | – | – | 1326.2 (62) | 1636.6 (45) |
| $T_{\text{max}}$, hour (range) | 2.2 (0.9–5.6) | 1.1 (0.5–3.0) | 1.0 (0.9–2.3) | 1.0 (0.5–8.3) |
| $t_{\text{max}}$, hour (standard deviation) | – | – | 6.1 (2.3) | 6.0 (1.6) |
| CL/F, L/hour (CV) | – | – | 15.1 (46) | 18.3 (63) |
| Vz/F, L (CV) | – | – | 125.1 (28) | 154.9 (44) |

*Geometric mean. †Median. ‡Arithmetic mean.

AUC, area under the curve; $C_{\text{max}}$, maximum plasma concentration; CL/F, apparent oral clearance; CV, coefficient of variation; QW, once weekly; $T_{\text{max}}$, time of maximum plasma concentration; TAK-228+P, TAK-228 once daily 3 mg; TAK-228 QW, TAK-228 once daily 3 mg; TAK-228+P TAK-228 QW TAK-228 once daily 3 mg; TAK-228 4 mg; fallopian tube cancer), 220 days (TAK-228 3 mg; ovarian cancer) and 368 days (TAK-228 4 mg; colon cancer) (online supplementary figure 3). The overall clinical benefit rate (CR+PR + SD) was 52.9% (9/17 patients). Apart from a greater incidence of SD in patients receiving 3 mg TAK-228, there were no notable trends in efficacy across the different dose levels.

With TAK-228+P, one patient (breast cancer) achieved a CR and three achieved PRs (one each with urinary bladder and uterine cancers (both TAK-228 6 mg), one with soft-tissue sarcoma (TAK-228 4 mg), resulting in an ORR of 18% (table 4). Seven patients achieved SD; one patient with ovarian cancer receiving TAK-228 6 mg plus paclitaxel maintained SD for ≥6 months (220 days) (online supplementary figure 3). The overall clinical benefit rate with TAK-228+P was 50% (11/22 patients): no notable trends were observed between the 4 mg and 6 mg TAK-228 doses.

No patient achieved an objective response with TAK-228 QW. Nine patients achieved SD; one patient with head and neck cancer receiving TAK-228 30 mg QW maintained SD for ≥6 months (225 days) (online supplementary figure 3). The overall clinical benefit rate with TAK-228 QW was 45% (9/20 patients). No notable trends were observed between the 20 mg and 30 mg TAK-228 doses.

**DISCUSSION**

This phase I study was designed to evaluate the safety and tolerability and PK of the investigational oral mTORC1/2 dual inhibitor TAK-228 when administered as milled TAK-228 either as a single agent or in combination with paclitaxel and to assess the effect of dosing conditions (fasted vs fed) on the PK of TAK-228. In addition, the study compared the PK of milled versus unmilled TAK-228 capsules and evaluated the preliminary efficacy.
Moore KN, et al
ESMO Open 2018;3:e000291. doi:10.1136/esmoopen-2017-000291

3

6

the RP2Ds; however, because patients receiving TAK-228 single-agent QD and QW TAK-228, the MTDs were also as TAK-228 4

2018;

3

2018;

3

6


















































































































































































































































































































































































































































































































































































































































































































































































































followed by a high-fat meal affected the rate, but not the extent, of TAK-228 absorption. There was an increase in the median $T_{max}$ from 2 hours to 6 hours and a decrease in the geometric mean $C_{max}$ of 40% that was considered clinically meaningful; however, there was no appreciable change in the AUC. The decrease in $C_{max}$ when TAK-228 is dosed with a high-fat meal and a change in dosing conditions (ie, requirement for fasted dosing from the previous studies that were flexible and allowed TAK-228 to be taken with food) may collectively help to explain the differences in TAK-228 tolerability observed in this study compared with earlier studies. Interestingly, there were no appreciable differences in the PK of TAK-228 4 mg capsules containing unmilled versus milled formulations when both were administered in a fasted state.

There were no noteworthy trends in efficacy across the different dosing schedules or levels in the study. The solid tumour types responding to single-agent TAK-228 treatment in this study show no striking differences with those reported in previous studies, with the exception of renal cancer. Indeed, TAK-228 is currently being investigated alone and in combination with the small-molecule PI3K-α inhibitor TAK-117 in patients with advanced or metastatic clear cell renal cell carcinoma (mccRCC).

In the current study, one patient with breast cancer achieved an objective response, while in a previous phase I TAK-228 trial, one patient with breast cancer had SD. These findings are consistent with previous preclinical evaluation of TAK-228 in breast cancer (ML20 and MCF7) xenograft models. Taken together, the efficacy of TAK-228 is in line with positive responses observed for everolimus in breast cancer, temsirolimus in endometrial cancer, and temsirolimus and everolimus in renal cell carcinoma.

Based on the pharmacological properties, safety profile and antitumour efficacy of TAK-228 in the current study, further investigation of TAK-228 as a single agent and in novel treatment combinations is warranted. Currently, a number of phase II clinical studies of TAK-228 are ongoing, including the study previously mentioned, which is investigating TAK-228 QW and QD ×3 days with or without TAK-117 in mccRCC compared with everolimus. Another study is underway to compare TAK-228 QD and QW in combination with fulvestrant versus fulvestrant alone in postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER-positive/HER2-negative) breast cancer. These other studies, together with the research presented here, will inform dosing considerations and treatment regimens (alone and in combination) for TAK-228.

Acknowledgements The authors would like to acknowledge all the patients who participated in these studies and their families, as well as all the investigators and site staff who made these studies possible. The authors would also like to thank Alexy Bulychiev and Andy Zhu of DMPK, Millennium Pharmaceuticals, Inc., for their contribution in GastroPlus modelling of the effect of particle size and food on the PK of TAK-228. Writing support was provided by Matthew Hallam and Ying Jean of Firekite, an Ashfield company, part of UDG Healthcare plc, during the development of this manuscript, which was funded by Millennium Pharmaceuticals, Inc., in compliance with Good Publication Practice 3 ethical guidelines (Battisti et al., Ann Intern Med 2015;163:461–4).

Contributors All authors listed on this manuscript declare that they were equally involved in the data acquisition and interpretation of data during this clinical trial as well as manuscript development and review for this submitted work.

Funding Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.

Competing interests NIM reports honoraria for advisory board work from Astra Zeneca, Advaxis, Clovis, Tesaro, Genentech/Roche, Immunogen, VBL Therapeutics, outside the submitted work. GSF reports research funding from Millennium for the work under consideration for publication and outside the submitted work. SC, RN, CP, AE and FZ are paid, full-time employees of Takeda Oncology, the sponsor of the clinical trial on which this manuscript is based. TMB and MRP have nothing to disclose.

Patient consent Not required.

Ethics approval Research was carried out in compliance with approval from institutional review boards/ethics committees in accordance with ethical principles found in the Declaration of Helsinki including International Conference on Harmonization, Good Clinical Practice regulations and guidelines and all applicable local regulations.

Provenance and peer review Not commissioned; internally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCEs

1. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009;122( Pt 20):3589–94.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
3. Moschetta M, Reale A, Marasco C, et al. Therapeutic targeting of the mTOR-signaling pathway in cancer: benefits and limitations. Br J Pharmacol 2011;164:1–13.
4. Schechun S, Brullo C, Musumeci F, et al. ATP-competitive inhibitors of mTOR: an update. Curr Med Chem 2011;18:2995–3014.
5. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603–10.
6. Harada K, Miyake H, Kumano M, et al. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. Br J Cancer 2013;109:2389–95.
7. Ghobrial IM, Siegel DS, Vij R, et al. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström’s macroglobulinemia. Am J Hematol 2016;91:400–5.
8. Voss M, Gordon MS, Mita M, et al. 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. Eur J Cancer 2015;51:572.
9. Khadka P, Ro J, Kim H, et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm 2014;9:304–16.
10. Loh ZH, Samanta AK, Sia Heng PW. Overview of milling technologies for improving the solubility of poorly water-soluble drugs. Asian J Pharm 2015;10:255–74.
11. Infante JR, Tabernero J, Cervantes A, et al. Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies. Mol Cancer Ther 2013;12(Suppl):C252.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–47.
13. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007;356:2271–81.
14. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. *Cancer* 2010;116:4256–65.
15. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:514–23.
16. Hess G, Herbrécht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. *J Clin Oncol* 2009;27:3822–9.
17. Xu J, Tian D. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis. *Curr Med Res Opin* 2014;30:67–74.
18. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2014;32:760–7.
19. Diamond J, Borges VF, Kabos P, et al. Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane (E) or fulvestrant (F) in postmenopausal women with ER + /HER2- metastatic breast cancer (MBC). *Annals of Oncology* 2016;27(suppl_6), 60.
20. Juric D, Lopez J, Rasco D, et al. A phase 1b multicenter, open-label study of investigational TAK-228 (MLN0128) plus TAK-117 (MLN1117) in adult patients with advanced nonhematologic malignancies. *Eur J Cancer* 2016;69:S11–S12.
21. Choueiri TK, Porta C, Suarez Rodriguez C, et al. 925TIPA phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy. *Annals of Oncology* 2017;28:295–329.
22. Gökmen-Polar Y, Liu Y, Toroni RA, et al. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. *Breast Cancer Res Treat* 2012;136:673–82.
23. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. *J Clin Oncol* 2009;27:2630–7.
24. Bachelot T, Bourig C, Crozet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. *J Clin Oncol* 2012;30:2718–24.
25. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012;366:520–9.
26. Oza AM, Elit L, Tsaos MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. *J Clin Oncol* 2011;29:3278–85.